University Cancer and Blood Center LLC

Summary

University Cancer and Blood Center LLC is a medical facility located in Athens, Georgia. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Pancreatic Cancer and other specialties. University Cancer and Blood Center LLC is involved with conducting 165 clinical trials across 193 conditions. There are 6 research doctors associated with this hospital, such as Sharad Ghamande, Petros Nikolinakos, Gustavo Westin, MD, and Kuang Chang, MD.

Top PIs

Clinical Trials running at University Cancer and Blood Center LLC

Lung Cancer

Breast Cancer

Cancer

Ovarian Cancer

Non-Small Cell Lung Cancer

Prostate Cancer

Breast cancer

Multiple Myeloma

Uterine Cancer

Endometrial Adenocarcinoma

Daraxonrasib

for Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Recruiting

2 awards

Phase 3

4 criteria

Amivantamab Combinations

for Non-Small Cell Lung Cancer

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Recruiting

1 award

Phase 2

3 criteria

Targeted Drug Therapy

for Non-Small Cell Lung Cancer

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.

Recruiting

1 award

Phase 2

28 criteria